Английская Википедия:Indacaterol/glycopyrronium bromide/mometasone
Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug
Indacaterol/glycopyrronium bromide/mometasone, sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma.[1] It contains indacaterol as acetate, glycopyrronium bromide, and mometasone furoate.[1]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1]
It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol, glycopyrronium bromide and mometasone furoate) in capsules, to be administered using an inhaler.[2] An optional electronic sensor may also be co-packed with the product.[2] The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient.[2] The sensor will send the data to an app on a smart phone or other suitable device.[2] It was approved for medical use in the European Union in July 2020.[1][3][4]
Medical uses
Indacaterol/glycopyrronium bromide/mometasone is indicated as a maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.[1]
Indacaterol is a long-acting beta-2 adrenergic receptor agonist.[1] It relaxes the muscle around the airways into the lungs by activating targets called beta-2 receptors in the muscle cells.[1] This helps to keep the airways open.[1]
Glycopyrronium bromide is a muscarinic receptor antagonist.[1] It blocks muscarinic receptors in muscle cells in the airways.[1] Because these receptors help control the contraction of the airway muscles, blocking them causes the muscles to relax, helping to keep the airways open.[1]
Mometasone is a corticosteroid that has anti-inflammatory effects.[1] It works in a similar way to corticosteroid hormones in the body, reducing the activity of the immune system (the body's defences).[1] Mometasone helps to keep the airways clear by blocking the release of substances, such as histamine, that are involved in inflammation and release of mucus in the airways.[1]
History
In April 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for Enerzair Breezhaler, a new asthma treatment which includes an optional digital sensor.[2][5] The CHMP also recommended granting a marketing authorization in the European Union for Zimbus Breezhaler which is a duplicate of Enerzair Breezhaler.[2][6]
Enerzair Breezhaler and Zimbus Breezhaler were approved for medical use in the European Union in July 2020.[1][3][4]
References
Шаблон:Drugs for obstructive airway diseases Шаблон:Adrenergic receptor modulators Шаблон:Muscarinic acetylcholine receptor modulators Шаблон:Portal bar
- ↑ 1,00 1,01 1,02 1,03 1,04 1,05 1,06 1,07 1,08 1,09 1,10 1,11 1,12 1,13 1,14 1,15 Шаблон:Cite web Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 2,0 2,1 2,2 2,3 2,4 2,5 Шаблон:Cite web Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 3,0 3,1 Шаблон:Cite web Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 4,0 4,1 Шаблон:Cite press release
- ↑ Шаблон:Cite press release
- ↑ Шаблон:Cite web
